Not Signed In -
Pneumonia |
|
|
Clinical Trial: A Safety and Efficacy Study of Hospitalized Patients with Community-Acquired Pneumonia and Sepsis
This study has been completed.
|
Purpose
The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Pneumonia Sepsis | Drug: Recombinant Chimeric Monoclonal Antibody | Phase II |
MedlinePlus related topics: Pneumonia; Sepsis
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Hospitalized Patients with Community-Acquired Pneumonia and Sepsis
Further Study Details:
Study start: May 2002
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Current diagnosis of community-acquired pneumonia.
- Evidence of systemic inflammatory response to infection.
Exclusion Criteria:
- Atypical or viral pneumonia based on clinical or epidemiologic suspicion by the investigator.
- Presence of organ failure.
Location Information
Washington
ICOS Corporation, Bothell, Washington, 98021, United States
More Information
Study ID Numbers: EPN01; EPN01
Record last reviewed: January 2004
Last Updated: October 13, 2004
Record first received: August 1, 2002
ClinicalTrials.gov Identifier: NCT00042588
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: January 2004
Last Updated: October 13, 2004
Record first received: August 1, 2002
ClinicalTrials.gov Identifier: NCT00042588
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
